Table 2 Overview of the literature on the (significant) relation between biomarker and the disease activity
Author | Population | No. | Biomarker | Classification | Results |
|---|---|---|---|---|---|
Mullan et al.9 | RA | 45 | C2C (baseline,1, 3, 6, 9,12-mo serum) | DAS28 responders vs. nonresponders (at 3 mo) | C2C ↓ |
|  | PsA | 17 | C1,2C | (responder: ≥0.6 improvement and DAS28 ≤5.1, nonresponder: <0.6 improvement OR DAS28 > 5.1) | NS |
| Â | (mean 11 yr, DAS28 > 3.2) | Â | CPII | Â | NS |
|  |  |  | ΔCOL (ΔC2C + ΔC1, 2C + ΔCPII) |  | ΔCOL ↓ |
Mullan et al.9 | RA | 45 | C2C (baseline,1, 3, 6, 9, 12-mo serum) |  | C2C ↓ at 1 mo |
|  | PsA | 17 | C1,2C | Remission vs. no remission | C1,2C ↓ at 1 mo |
| Â | (mean, 11 yr, | Â | CPII | (remission = DAS28 <2.6 at 6 mo) | NS |
|  | DAS28 > 3.2) |  | ΔCOL (ΔC2C + ΔC1,2C + ΔCPII) |  | ΔCOL ↓ change 1 mo |